How regulatory CD25+CD4+ T cells impinge on tumor immunobiology: The differential response of tumors to therapies

Journal of Immunology

Volumn 179, Issue 9, 2007, Pages 5659-5668

  Leon, Kalet ^a,b   Garcia, Karina ^a   Carneiro, Jorge ^b   Lage, Agustin ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b Instituto Gulbenkian de Ciência ^*  (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; INTERLEUKIN 2 RECEPTOR ALPHA;

ARTICLE; AUTOIMMUNITY; CANCER IMMUNIZATION; CANCER SURGERY; CD4+ CD25+ T LYMPHOCYTE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNOLOGY; BIOLOGICAL MODEL; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; VACCINATION;

CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MODELS, IMMUNOLOGICAL; NEOPLASMS; VACCINATION;

EID: 38349154060     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.9.5659     Document Type: Article

References (48)

1. Beyer, M., and J. L. Schultze. 2006. Regulatory T cells in cancer. Blood 108: 804-811.
2. Knutson, K. L., M. L. Disis, and L. G. Salazar. 2006. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol. Immunother. 56: 271-285.
3. Yamaguchi, T., and S. Sakaguchi. 2006. Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol. 16: 115-123.
4. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163: 5211-5218.
5. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59: 3128-3133.
6. high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother. 55: 1064-1071.
7. Wolf, D., A. M. Wolf, H. Rumpold, H. Fiegl, A. G. Zeimet, E. Muller-Holzner, M. Deibl, G. Gastl, E. Gunsilius, and C. Marth. 2005. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11: 8326-8331.
8. + regulatory T cell is increased in the patients with ovarian carcinoma. Cancer Invest. 23: 399-403.
9. + regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA 102: 9253-9257.
10. + regulatory T cells in normal and tumor-bearing mice. Int. Immunopharmacol. 4: 1785-1793.
11. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
12. Woo, E. Y., H. Yeh, C. S. Chu, K. Schlienger, R. G. Carroll, J. L. Riley, L. R. Kaiser, and C. H. June. 2002. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168: 4272-4276.
13. + T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors. J. Immunol. 176: 7325-7334.
14. + regulatory T cells. J. Exp. Med. 201: 681-686.
15. Zhou, G., C. G. Drake, and H. I. Levitsky. 2006. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107: 628-636.
16. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. USA 100: 10902-10906.
17. + T cells impinge on tumor immunobiology: on the existence of two alternative dynamical classes of tumors. J. Theor. Biol. 247: 122-137.
18. Wall, E., K. Milne, M. Martin, P. Watson, P. Theiss, and B. Nelson. 2007. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res. 67: 6442-6450.
19. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24: 1169-1177.
20. + T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12: 465-472.
21. Leong, P. P., R. Mohammad, N. Ibrahim, H. Ithnin, M. Abdullah, W. C. Davis, and H. F. Seow. 2006. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol. Lett. 102: 229-236.
22. DeLong, P., R. G. Carroll, A. C. Henry, T. Tanaka, S. Ahmad, M. S. Leibowitz, D. H. Sterman, C. H. June, S. M. Albelda, and R. H. Vonderheide. 2005. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol. Ther. 4: 342-346.
23. Fox, S. B., R. Launchbury, G. J. Bates, C. Han, N. Shaida, P. R. Malone, A. L. Harris, and A. H. Banham. 2007. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2α but not HIF-1α. Prostate 67: 623-629.
24. Carneiro, J., K. Leon, I. Caramalho, C. Van den Dool, R. Gardner, V. Oliveira, M. Bergman, N. Sepúlveda, T. Paixão, J. Faro, and J. Demengeot. 2007. When three is not a crowd: a crossregulation model of the dynamics and repertoire selection of regulatory CD4 T cells. Immunol. Rev. 216: 48-68.
25. Leon, K., R. Perez, A. Lage, and J. Carneiro. 2000. Modelling T-cell-mediated suppression dependent on interactions in multicellular conjugates. J. Theor. Biol. 207: 231-254.
26. Leon, K., R. Perez, A. Lage, and J. Carneiro. 2001. Three-cell interactions in T cell-mediated suppression? A mathematical analysis of its quantitative implications. J. Immunol. 166: 5356-5365.
27. Leon, K. 2002. A Quantitative Approach to Dominant Tolerance. University of Porto, Porto, Portugal.
28. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201: 779-791.
29. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25: 207-217.
30. Dannull, J., Z. Su, D. Rizzieri, B. K. Yang, D. Coleman, D. Yancey, A. Zhang, P. Dahm, N. Chao, E. Gilboa, and J. Vieweg. 2005. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115: 3623-3633.
31. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96: 2982-2987.
32. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
33. Engelhorn, M. E., J. A. Guevara-Patino, G. Noffz, A. T. Hooper, O. Lou, J. S. Gold, B. J. Kappel, and A. N. Houghton. 2006. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat. Med. 12: 198-206.
34. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344.
35. Motoyoshi, Y., K. Kaminoda, O. Saitoh, K. Hamasaki, K. Nakao, N. Ishii, Y. Nagayama, and K. Eguchi. 2006. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol. Rep. 16: 141-146.
36. + cells on the generation of immunity to tumour cell lines in mice. Novartis Found. Symp. 256: 149-152; discussion 152-169.
37. Knutson, K. L., Y. Dang, H. Lu, J. Lukas, B. Almand, E. Gad, E. Azeke, and M. L. Disis. 2006. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177: 84-91.
38. Choudhury, A., S. Mosolits, P. Kokhaei, L. Hansson, M. Palma, and H. Mellstedt. 2006. Clinical results of vaccine therapy for cancer: learning from history for improving the future. Adv Cancer Res. 95: 147-202.
39. Izawa, J. I., J. L. Chin, and E. Winquist. 2006. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer. Can. J. Urol. 13 (Suppl. 3): 48-53.
40. Potti, A., and A. K. Ganti. 2006. Adjuvant chemotherapy for early-stage nonsmall cell lung cancer: the past, the present and the future. Exp. Opin. Biol. Ther. 6: 709-716.
41. Cappuccio, A., M. Elishmereni, and Z. Agur. 2006. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res. 66: 7293-7300.
42. Frieboes, H. B., X. Zheng, C. H. Sun, B. Tromberg, R. Gatenby, and V. Cristini. 2006. An integrated computational/experimental model of tumor invasion. Cancer Res. 66: 1597-1604.
43. de Pillis, L. G., A. E. Radunskaya, and C. L. Wiseman. 2005. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 65: 7950-7958.
44. Castiglione, F., and B. Piccoli. 2006. Optimal control in a model of dendritic cell transfection cancer immunotherapy. Bull. Math Biol. 68: 255-274.
45. de Pillis, L. G., W. Gu, and A. E. Radunskaya. 2006. Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. J. Theor. Biol. 238: 841-862.
46. Matzavinos, A., M. A. Chaplain, and V. A. Kuznetsov. 2004. Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. Math. Med. Biol. 21: 1-34.
47. Wodarz, D., and V. A. Jansen. 2003. A dynamical perspective of CTL cross-priming and regulation: implications for cancer immunology. Immunol. Lett. 86: 213-227.
48. Takayanagi, T., and A. Ohuchi. 2001. A mathematical analysis of the interactions between immunogenic tumor cells and cytotoxic T lymphocytes. Microbiol. Immunol. 45: 709-715.